Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director · HEAD OF R&D, COO-NOVITIUM OPS | February 26, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,056 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 11,116 · Balance 101,056 F1: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Esjay LLC | 431,920 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 431,920 F2: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. |
| Common StockSEC Table I · non-derivative | IndirectHeld by SS Pharma LLC | 5,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,000 F3: The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
F2: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
F3: The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Mar 2, 2026 22:59 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 11,116 | $77.15 | $857,599.40 |
DisclosureSEC source: 0001870913-26-000005 · wk-form4_1772492383.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,056 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,898 | $76.25 | $220,972.50 |
DisclosureSEC source: 0001870913-26-000002 · wk-form4_1771016786.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,940 F1 · shares: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. F2 · balance_after: Includes 250 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 22:10 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 52,988 | $90.44 | $4,792,234.72 |
DisclosureSEC source: 0001870913-25-000008 · wk-form4_1755900596.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 431,920 F3 · price: The shares were sold in multiple trades at prices ranging from $89.90 to $91.44. The price reported above reflects the weighted average sales price. F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 22:10 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 47,012 | $90.27 | $4,243,773.24 |
DisclosureSEC source: 0001870913-25-000008 · wk-form4_1755900596.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 484,908 F1 · price: The shares were sold in multiple trades at prices ranging from $89.21 to $90.83. The price reported above reflects the weighted average sales price. F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 20:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 52,990 | $87.15 | $4,618,078.50 |
DisclosureSEC source: 0001870913-25-000006 · wk-form4_1755549120.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 531,920 F3 · price: The shares were sold in multiple trades at prices ranging from $85.44 to $90.00. The price reported above reflects the weighted average sales price. F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 47,010 | $89.48 | $4,206,454.80 |
DisclosureSEC source: 0001870913-25-000006 · wk-form4_1755549120.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 584,910 F1 · price: The shares were sold in multiple trades at prices ranging from $88.20 to $90.11. The price reported above reflects the weighted average sales price. F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:21 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 700 | $76.83 | $53,781.00 |
DisclosureSEC source: 0001870913-25-000004 · wk-form4_1747167705.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 631,920 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2024. F2 · price: The shares were sold in multiple trades at prices ranging from $76.11 to $76.95. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 9,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001870913-25-000002 · wk-form4_1739927992.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,588 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 14,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001870913-25-000002 · wk-form4_1739927992.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,014 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 21:30 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 2,743 | $62.00 | $170,066.00 |
DisclosureSEC source: 0001870913-24-000028 · wk-form4_1721424608.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 632,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $61.01 to $62.92. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 17, 2024 Filed Jul 17, 2024 23:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,257 | $63.16 | $900,472.12 |
DisclosureSEC source: 0001870913-24-000026 · wk-form4_1721257659.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 635,363 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F5 · price: The shares were sold in multiple trades at prices ranging from $62.62 to $64.21. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 23:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 22,000 | $64.27 | $1,413,940.00 |
DisclosureSEC source: 0001870913-24-000026 · wk-form4_1721257659.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 649,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F4 · price: The shares were sold in multiple trades at prices ranging from $63.25 to $64.91. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,000 | $63.38 | $697,180.00 |
DisclosureSEC source: 0001870913-24-000026 · wk-form4_1721257659.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 671,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $62.47 to $64.19. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 20:12 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 20,000 | $58.90 | $1,178,000.00 |
DisclosureSEC source: 0001870913-24-000024 · wk-form4_1719259916.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 682,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $58.43 to $59.48. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 23:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,447 | $59.86 | $685,217.42 |
DisclosureSEC source: 0001870913-24-000022 · wk-form4_1718925060.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 702,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F5 · price: The shares were sold in multiple trades at prices ranging from $59.40 to $60.50. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 23:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,607 | $60.76 | $644,481.32 |
DisclosureSEC source: 0001870913-24-000022 · wk-form4_1718925060.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 714,067 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F4 · price: The shares were sold in multiple trades at prices ranging from $60.33 to $61.82. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 23:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 7,946 | $61.41 | $487,963.86 |
DisclosureSEC source: 0001870913-24-000022 · wk-form4_1718925060.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 724,674 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $60.77 to $62.55. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:21 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 12,855 | $61.81 | $794,567.55 |
DisclosureSEC source: 0001870913-24-000020 · wk-form4_1716326500.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 732,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $61.44 to $62.36. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| May 17, 2024 Filed May 17, 2024 22:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,836 | $62.09 | $362,357.24 |
DisclosureSEC source: 0001870913-24-000018 · wk-form4_1715983489.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 745,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F5 · price: The shares were sold in multiple trades at prices ranging from $61.43 to $64.00. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| May 16, 2024 Filed May 17, 2024 22:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 16,459 | $63.84 | $1,050,742.56 |
DisclosureSEC source: 0001870913-24-000018 · wk-form4_1715983489.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 751,311 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F4 · price: The shares were sold in multiple trades at prices ranging from $63.28 to $64.90. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,850 | $65.86 | $978,021.00 |
DisclosureSEC source: 0001870913-24-000018 · wk-form4_1715983489.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 767,770 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $64.66 to $66.54. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 22:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 16,809 | $65.17 | $1,095,442.53 |
DisclosureSEC source: 0001870913-24-000016 · wk-form4_1713824793.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 782,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F4 · price: The shares were sold in multiple trades at prices ranging from $64.20 to $65.79. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 22:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,423 | $64.98 | $677,286.54 |
DisclosureSEC source: 0001870913-24-000016 · wk-form4_1713824793.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 799,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $64.43 to $65.89. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| April 17, 2024 Filed Apr 17, 2024 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 9,520 | $65.40 | $622,608.00 |
DisclosureSEC source: 0001870913-24-000014 · wk-form4_1713385980.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 809,852 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F5 · price: The shares were sold in multiple trades at prices ranging from $65.04 to $66.06. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,834 | $66.20 | $386,210.80 |
DisclosureSEC source: 0001870913-24-000014 · wk-form4_1713385980.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 819,372 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F4 · price: The shares were sold in multiple trades at prices ranging from $66.01 to $66.58. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 7,414 | $66.33 | $491,770.62 |
DisclosureSEC source: 0001870913-24-000014 · wk-form4_1713385980.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 825,206 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The shares were sold in multiple trades at prices ranging from $65.65 to $67.27. The price reported above reflects the weighted average sales price. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:43 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $67.17 | $671,700.00 |
DisclosureSEC source: 0001870913-24-000012 · wk-form4_1710196991.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 832,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $66.51 to $67.81, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 02:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 15,085 | $66.35 | $1,000,889.75 |
DisclosureSEC source: 0001870913-24-000010 · wk-form4_1709863910.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 842,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $65.53 to $67.00, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 02:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,822 | $65.47 | $970,396.34 |
DisclosureSEC source: 0001870913-24-000010 · wk-form4_1709863910.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 857,705 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.84 to $66.04, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,093 | $65.35 | $659,577.55 |
DisclosureSEC source: 0001870913-24-000010 · wk-form4_1709863910.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 872,527 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.45 to $66.58, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:18 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,122 | $67.67 | $75,925.74 |
DisclosureSEC source: 0001870913-24-000008 · wk-form4_1709331498.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,652 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:53 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 8,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001870913-24-000006 · wk-form4_1708120376.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,774 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:53 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 13,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001870913-24-000006 · wk-form4_1708120376.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,828 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 22:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 15,000 | $56.44 | $846,600.00 |
DisclosureSEC source: 0001870913-24-000004 · wk-form4_1706049128.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 882,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $56.00 to $57.11, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 22:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,692 | $55.95 | $318,467.40 |
DisclosureSEC source: 0001870913-24-000004 · wk-form4_1706049128.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 897,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $55.63 to $56.21, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,524 | $55.57 | $251,398.68 |
DisclosureSEC source: 0001870913-24-000004 · wk-form4_1706049128.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 903,312 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $55.03 to $56.00, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| January 18, 2024 Filed Jan 18, 2024 23:20 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 9,784 | $55.30 | $541,055.20 |
DisclosureSEC source: 0001870913-24-000002 · wk-form4_1705619998.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 907,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $54.70 to $55.73, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 23:20 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $55.11 | $551,100.00 |
DisclosureSEC source: 0001870913-24-000002 · wk-form4_1705619998.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 917,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $54.59 to $55.57, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:20 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,000 | $55.63 | $278,150.00 |
DisclosureSEC source: 0001870913-24-000002 · wk-form4_1705619998.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 927,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $54.99 to $56.71, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 22:44 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 25,000 | $52.65 | $1,316,250.00 |
DisclosureSEC source: 0001870913-23-000020 · wk-form4_1703025852.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 932,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.45 to $53.19, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 22:44 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 13,026 | $52.44 | $683,083.44 |
DisclosureSEC source: 0001870913-23-000020 · wk-form4_1703025852.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 957,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.02 to $52.97, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:44 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,974 | $52.44 | $627,916.56 |
DisclosureSEC source: 0001870913-23-000020 · wk-form4_1703025852.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 970,646 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.97 to $52.97, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 02:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 13,000 | $51.00 | $663,000.00 |
DisclosureSEC source: 0001870913-23-000018 · wk-form4_1700532348.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 982,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.70 to $51.43, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 16, 2023 Filed Nov 16, 2023 23:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,448 | $51.66 | $333,103.68 |
DisclosureSEC source: 0001870913-23-000013 · wk-form4_1700176267.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 996,430 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.14 to $52.70, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:58 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,448 | $51.66 | $333,103.68 |
DisclosureSEC source: 0001870913-23-000016 · wk-form4a_1700531880.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 995,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.14 to $52.70, inclusive F3 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 23:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 7,647 | $53.64 | $410,185.08 |
DisclosureSEC source: 0001870913-23-000013 · wk-form4_1700176267.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,002,878 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.96 to $54.24, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 15, 2023 Filed Nov 21, 2023 01:58 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 7,647 | $53.64 | $410,185.08 |
DisclosureSEC source: 0001870913-23-000016 · wk-form4a_1700531880.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,002,068 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.96 to $54.24, inclusive. F3 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 22,095 | $53.17 | $1,174,791.15 |
DisclosureSEC source: 0001870913-23-000013 · wk-form4_1700176267.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,010,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.95 to $54.07, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 14, 2023 Filed Nov 21, 2023 01:58 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 22,905 | $53.17 | $1,217,858.85 |
DisclosureSEC source: 0001870913-23-000016 · wk-form4a_1700531880.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,009,715 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.95 to $54.07, inclusive. F3 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| October 19, 2023 Filed Oct 19, 2023 20:28 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $57.06 | $570,600.00 |
DisclosureSEC source: 0001870913-23-000011 · wk-form4_1697747306.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,032,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $56.50 to $57.69, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.